Indication
Staphylococcus aureus bloodstream infection
1 clinical trial
2 products
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of XJ101 in Chinese Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-04-28
Product
PlaceboProduct
XJ101